Acandis GmbH is proud to announce the completion of its merger with Angionautix, the Spain- and Latin America-based neurovascular distribution specialist. Angionautix will continue to operate under its own brand and culture, with its founding team firmly in place to lead its next chapter of growth.
A team that built something exceptional
At the heart of this announcement is a simple truth: Angionautix CEO Alberto Pérez-Rosado and his team built something exceptional. Starting from scratch, they assembled a company with outstanding clinical relationships, a hard-won regulatory presence across multiple geographies, and a culture defined by quality and ambition. Their work has earned the trust of clinicians and hospital systems across Spain, Portugal and Latin America — and that trust is one of the most valuable things Angionautix brings to the combined group.
To the entire Angionautix team and customers: this merger is not a conclusion. It is a beginning.
Stronger together
Joining forces with Acandis opens a new frontier for Angionautix. With access to a broader product portfolio, deeper R&D capabilities, and a European operational backbone, the Angionautix team will be better equipped than ever to serve its markets and its patients.
And for Acandis, Angionautix unlocks a meaningful and immediate presence in some of the world’s most dynamic markets for neurovascular care.
“Today marks an important milestone in Acandis’ journey to become a leading global neurovascular company. What impressed us from the very beginning was the exceptional business that the Angionautix team has built, their strong clinical relationships, deep market expertise and unwavering commitment to patient care. We share the same passion for innovation, excellence and supporting physicians in delivering life-saving treatments. Together, we are creating a stronger platform that will expand access to advanced neurovascular technologies across Spain, Portugal, Chile and Mexico. We are delighted to welcome the entire Angionautix team to the Acandis family and look forward to building the future together,” said Andreas Schüssler, CEO, and Kirsi Schüssler, President, of Acandis.
“We are proud of what we have done so far and the great team we created, but our very demanding business requires a continuous will to innovate and adapt our organizations to the new challenges ahead. This integration with Acandis, the most cutting-edge neurovascular manufacturer, opens a bright future for us. We are now one team focused on serving our customers in all the steps from R&D to clinical practice,” said Alberto Pérez-Rosado, CEO of Angionautix.
Lauxera Capital Partners, Acandis’ investor and strategic partner, has supported this transaction as a key step in building a truly global neurovascular platform.
“Angionautix was the perfect match for Acandis’ sense of excellence, professionalism and passion for delivering critical care to patients globally. We are thrilled to partner with them and to strengthen our direct presence in key markets,” said Edoardo Fracchia, Partner at Lauxera Capital Partners.
About Acandis
Acandis GmbH is a Pforzheim-based, owner-managed medical device company specializing in the development, manufacture and marketing of minimally invasive solutions for the treatment of neurovascular disease. Founded in 2006, the company is fully vertically integrated, with development and manufacturing at its German headquarters in Baden-Württemberg.
Acandis offers a comprehensive portfolio of devices for both ischaemic and haemorrhagic stroke, including stents, flow diverters, thrombectomy devices and catheters, and is commercially present in more than 60 countries across Europe, Latin America, Asia and India.
For more information, visit www.acandis.com.
About Angionautix
Angionautix S.L. is a Madrid-based specialist distributor of endovascular devices, focused primarily on neurovascular pathology and supported by a team with more than 20 years of experience in the field. The company distributes, implements and provides clinical training on minimally invasive technologies for the treatment of vascular disease.
Angionautix serves clinicians and hospital systems across Spain, Portugal and Latin America, including Chile and Mexico.
For more information, visit www.angionautix.com.
Advisors to the Transaction:
Acandis & Lauxera Capital Partners: Alvarez & Marsal (financial due diligence), Haver & Mailänder (legal counsel), Marimón Abogados (legal & tax counsel)
Angionautix Shareholders: Banca March (financial advisor)
